Stephen E. Karp
- Cancer Research top 2%
- Breast Cancer Treatment Studies 7
-
- Breast Lesions and Carcinomas 4
- Oncology top 5%
- CAR-T cell therapy research 3
- Immunology top 5%
- Immunotherapy and Immune Responses 8
- Genetics top 5%
- Virus-based gene therapy research 6
- BRCA gene mutations in cancer 4
-
- Cancer Research and Treatments 4
-
- RNA Interference and Gene Delivery 3
- Co-authors
- William D. FoulkesNicholas P. RestifoSteven A. RosenbergJames J. MuléRami YounanMuriel BrackstoneAndré RobidouxClaire Holloway
- Partner nations
- United StatesCanadaAustralia
In The Last Decade
Stephen E. Karp
23 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 98
- Cancer Research 946
- Pathology and Forensic Medicine 566
- Oncology 783
- Immunology 559
- Genetics 568
Countries citing papers authored by Stephen E. Karp
This map shows the geographic impact of Stephen E. Karp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen E. Karp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen E. Karp more than expected).
Fields of papers citing papers by Stephen E. Karp
This network shows the impact of papers produced by Stephen E. Karp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen E. Karp. The network helps show where Stephen E. Karp may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Stephen E. Karp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Studybreakdown → | 2014 | 555 |
| 2 | 2013 | 3 | |
| 3 | 2013 | 2 | |
| 4 | 2003 | 20 | |
| 5 | 2001 | 3 | |
| 6 | 2000 | 8 | |
| 7 | 2000 | 10 | |
| 8 | 1999 | 55 | |
| 9 | 1998 | 11 | |
| 10 | 1997 | 7 | |
| 11 | 1997 | 131 | |
| 12 | 1997 | 1 | |
| 13 | Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. | 1997 | 92 |
| 14 | 1995 | 33 | |
| 15 | 1994 | 485 | |
| 16 | 1993 | 22 | |
| 17 | 1992 | 23 | |
| 18 | 1992 | 140 | |
| 19 | 1992 | 33 | |
| 20 | 1989 | 288 |
About Stephen E. Karp
Stephen E. Karp is a scholar working on Cancer Research, Biotechnology, Immunology, Genetics and Oncology, having authored 23 papers that have together received 2.2k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (8 papers), Breast Cancer Treatment Studies (7 papers), Virus-based gene therapy research (6 papers), Cancer Research and Treatments (4 papers), BRCA gene mutations in cancer (4 papers), Breast Lesions and Carcinomas (4 papers), CAR-T cell therapy research (3 papers) and RNA Interference and Gene Delivery (3 papers). The work is most often cited by research in Cancer Research (946 citations), Pathology and Forensic Medicine (566 citations), Oncology (783 citations), Immunology (559 citations) and Genetics (568 citations). Stephen E. Karp has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include William D. Foulkes, Nicholas P. Restifo, Steven A. Rosenberg, James J. Mulé, Rami Younan, Muriel Brackstone, André Robidoux, Claire Holloway, David R. McCready and Brigitte Poirier. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Human Gene Therapy, The Journal of Immunology and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.